AGP Executive Report
Last update: 6 hours agoEU-Canada Dealmaking: European Commission President Ursula von der Leyen floated the idea of Canada becoming the EU’s first “associate member,” with talks framed as an “alliance for the future” covering defence, intelligent manufacturing, tech, energy, critical minerals and the Arctic—though there’s no treaty category for it yet and details are still undefined. Liechtenstein in the Crosshairs of Trade: Russia extended its ban on imports of Western food products through end-2028, explicitly including Liechtenstein among affected countries, covering meat, seafood, dairy, fruits and vegetables. Pharma Approvals for Liechtenstein Markets: The EU’s CHMP backed Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) as perioperative treatment for resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q4 2026 and coverage including Liechtenstein. Solar Supply Chain Costs: A new U.S. Section 232 move sets minimum import prices and new tariffs on polysilicon and downstream solar products, with Switzerland and Liechtenstein listed among countries receiving capped treatment. Space & Research Access: Liechtenstein-linked CSA and Starlab are building a pathway for experiments to reach microgravity on the ISS, with selected projects gaining free ISS access. Digital Banking Upgrade: CA next bank became Switzerland’s first live user of Avaloq’s new mobile banking app, expanding secure self-service for payments and investments.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27123886-930626510-5eb41dddc2582afbc99f50c263359de127e4fa9c-5500x4000-100x73.jpeg)
